GPCRs and Receptor Pathways: How Peptide Signals Become Cell Responses

Every GPCR shares one body plan: a single protein chain that crosses the cell membrane seven times, creating an extracellular face that receives the signal and an intracellular face that transmits it. The ligand — a peptide, in this library's cases — binds the outer face and the loops between helices; binding shifts the packing of the seven helices; and that conformational change remodels the inner face into a shape that activates partners waiting inside the cell.

The receptor is, in the strictest sense, a shape-change machine: nothing passes through it. The signal that crosses the membrane is pure conformation.

The family is enormous — several hundred members in humans, the largest receptor family in the genome — and it subdivides into classes. Two matter for this library: class A (the rhodopsin-like majority, including the melanocortin receptors and the ghrelin receptor GHS-R1a) and class B (the secretin-like class built for peptide hormones, with a large extracellular domain that first captures the peptide — including the GLP-1, GIP, glucagon, and GHRH receptors). The class B two-step — the extracellular domain grabs the peptide's C-terminal half, then delivers its N-terminus into the helical core — is why those receptors handle 29-to-44-residue ligands that class A binding pockets never could.

The receptor's inner face activates a heterotrimeric G protein — three subunits (α, β, γ) parked at the membrane. The α-subunit is a switch that is off when holding GDP and on when holding GTP. An activated receptor works as an exchange catalyst: it pries the GDP out of Gα, GTP floods in, and the switched-on Gα (and the βγ pair) release to go regulate targets.

The elegance is the built-in timer: Gα slowly hydrolyzes its own GTP back to GDP, switching itself off and reassembling the trimer. Every activation is self-terminating — signaling is a rate, not a state.

Which targets Gα regulates depends on its type, and this is where receptor identity becomes signal identity:

• Gs — stimulates adenylyl cyclase, the enzyme that makes cAMP.
• Gi — inhibits the same enzyme, lowering cAMP.
• Gq — activates phospholipase C, cleaving a membrane lipid into IP₃ (which releases calcium from internal stores) and DAG.

cAMP and calcium are second messengers — small, fast-diffusing molecules produced in bulk the moment a receptor fires. One occupied receptor activates many G proteins; each activated cyclase makes many cAMP molecules; each downstream kinase phosphorylates many substrates. The cascade is an amplifier, which is how sub-nanomolar peptide concentrations — the EC50 range reported throughout the receptor literature — produce full cellular responses.

The two pathways relevant to this catalog, end to end:

The Gs/cAMP pathway. Receptor → Gs → adenylyl cyclase → cAMP → protein kinase A → phosphorylation of enzymes and transcription factors (CREB among them). This is the pathway of the class B peptide receptors: GLP-1R, GIPR, GCGR, and GHRH-R all signal predominantly through Gs — which is why cAMP accumulation is the standard readout in every incretin and GHRH-analogue characterization this library cites.

The Gq/calcium pathway. Receptor → Gq → phospholipase C → IP₃ → calcium release → calcium-dependent kinases and effectors. This is GHS-R1a's pathway — the ghrelin receptor — which is why ipamorelin-class characterization reads out calcium flux, and why the CJC-1295 + ipamorelin pairing is genuinely a two-pathway experiment: one blend, one cell type, cAMP and calcium arms running in parallel.

The melanocortin receptors (MC1R–MC5R) are class A but Gs-coupled — small receptors, big-pathway overlap with the class B peptides — which is why melanocortin assays also read cAMP despite the different receptor class.

Activated GPCRs are also phosphorylated by receptor kinases and then bound by β-arrestin — a protein that does two jobs at once: it desensitizes the receptor (blocking further G-protein coupling and driving internalization), and it signals in its own right, scaffolding a second wave of pathway activity independent of G proteins.

The consequence that matters for reading modern receptor papers: a ligand can activate the G-protein arm and the arrestin arm to different degrees. That is biased agonism — and it is not a curiosity but a designed property of compounds in this library: tirzepatide's published GIPR profile shows full cAMP efficacy with reduced β-arrestin recruitment relative to native GIP, the exact phenomenon that makes single-readout assays incomplete, as the receptor-comparison article details. Two assays, two rankings, both true — bias is why.

The standard vocabulary of the papers this library cites, decoded by the machinery above:

• EC50 — ligand concentration producing half-maximal response in a chosen readout; a pathway-specific number (a cAMP EC50 and an arrestin EC50 for the same ligand can differ enormously).
• Ki — binding affinity from competition assays; about occupancy, not signaling.
• Efficacy — the ceiling: full agonists reach the system's maximum, partial agonists plateau below it.
• Selectivity — the potency pattern across receptor subtypes, the axis on which single, dual, and triple agonists and selective versus pan-agonists are defined.
• Recombinant cell line — cells engineered to express one chosen receptor, so a measured response is attributable; the reason cross-paper EC50s compare only approximately, since receptor density and cell background shift absolute numbers.

Which is, finally, the analytical connection: receptor assays run at nanomolar concentrations, where tiny amounts of the wrong molecule matter. An impurity with its own receptor activity — a deletion sequence or oxidized variant — contributes signal the experiment will attribute to the named compound. Receptor pharmacology is only as interpretable as the identity and purity of what went into the well; Certificates of Analysis are published on product pages as testing is completed.